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Abstract
Deficiency of glucocerebrosidase (GBA) causes Gaucher disease (GD). In the common
non-neuronopathic GD type I variant, glucosylceramide accumulates primarily in the lyso-
somes of visceral macrophages. Supplementing storage cells with lacking enzyme is
accomplished via chronic intravenous administration of recombinant GBA containing
mannose-terminated N-linked glycans, mediating the selective uptake by macrophages
expressing mannose-binding lectin(s). Two recombinant GBA preparations with distinct N-
linked glycans are registered in Europe for treatment of type I GD: imiglucerase (Genzyme),
contains predominantly Man(3) glycans, and velaglucerase (Shire PLC) Man(9) glycans.
Activity-based probes (ABPs) enable fluorescent labeling of recombinant GBA preparations
through their covalent attachment to the catalytic nucleophile E340 of GBA. We compara-
tively studied binding and uptake of ABP-labeled imiglucerase and velaglucerase in isolated
dendritic cells, cultured human macrophages and living mice, through simultaneous detec-
tion of different GBAs by paired measurements. Uptake of ABP-labeled rGBAs by dendritic
cells was comparable, as well as the bio-distribution following equimolar intravenous admin-
istration to mice. ABP-labeled rGBAs were recovered largely in liver, white-blood cells, bone
marrow and spleen. Lungs, brain and skin, affected tissues in severe GD types II and III,
were only poorly supplemented. Small, but significant differences were noted in binding and
uptake of rGBAs in cultured human macrophages, in the absence and presence of mannan.
Mannan-competed binding and uptake were largest for velaglucerase, when determined
with single enzymes or as equimolar mixtures of both enzymes. Vice versa, imiglucerase
showed more prominent binding and uptake not competed by mannan. Uptake of recombi-
nant GBAs by cultured macrophages seems to involve multiple receptors, including several
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mannose-binding lectins. Differences among cells from different donors (n = 12) were
noted, but the same trends were always observed. Our study suggests that further insight in
targeting and efficacy of enzyme therapy of individual Gaucher patients could be obtained
by the use of recombinant GBA, trace-labeled with an ABP, preferably equipped with an
infrared fluorophore or other reporter tag suitable for in vivo imaging.
Introduction
Glucocerebrosidase (GBA) is a retaining β-glucosidase that hydrolyzes the glyco-sphingolipid
glucosylceramide in the lysosome [1–3]. Deficiency of GBA activity causes Gaucher disease
(GD), the most common inherited lysosomal storage disorder [1–3]. Symptoms include hepa-
tosplenomegaly, cytopenia and osteopenia [4–6], with highly variable manifestations, ranging
from the (common) non-neuronopathic GD type I variant to more severe manifestations with
lethal neurological complications (GD type II and III) and extreme cases with abnormalities in
skin permeability (collodion babies) [4–6].
In type I Gaucher disease, lysosomal accumulation of glucosylceramide is mostly restricted
to visceral macrophages, named Gaucher cells [4–10]. Macrophages are primarily affected by
the deficiency of GBA, due to high rates of lysosomal breakdown of complex glycosphingoli-
pids following phagocytosis of senescent erythrocytes and apoptotic cells, as well as uptake of
lipoproteins [11–15]. Gaucher cells are believed to cause many of the visceral symptoms [4–6]
and the prevention and/or removal of these lipid-laden macrophages has been formulated as a
rational target for treatment of type I GD [16, 17]. Brady and colleagues developed an elegant
approach to specifically supplement visceral macrophages with exogenous GBA [18, 19],
exploiting the presence of mannose-binding lectin(s) in this cell-type [20–25]. Isolated placen-
tal GBA, containing four N-linked glycans, largely of the complex type, was enzymatically
modified to expose terminal mannose-moieties (alglucerase, CeredaseTM, Genzyme) [26, 27].
Later on, human GBA was produced in CHO cells [28, 29], and comparably modified [28].
The recombinant enzyme, named imiglucerase (CerezymeTM, Genzyme), contains largely
Man(3) N-linked glycans [30–32]. Enzyme therapy with imiglucerase results in impressive
clinical responses in type I GD patients [33, 34] and is a worldwide registered therapy for this
disorder.
More recently, an alternative recombinant GBA has been produced by Shire PLC [35],
using the method of gene-activation, resulting in an enzyme (velaglucerase, VPRIVTM) with
largely Man(9) N-linked glycans [30, 32]. The latter enzyme recently received orphan drug sta-
tus in Europe and the USA, based on the successful outcome of clinical trials with type I GD
patients [35]. Recently, another recombinant GBA, produced in plant cells (taliglucerase,
ElelysoTM, Protalix/Pfizer) [30, 32, 36, 37], was registered in the USA and Europe, but this
enzyme received no orphan drug status in Europe and consequently its use on this continent is
restricted [38].
The availability in Europe of two comparably costly, recombinant GBA preparations, differ-
ing in N-linked glycan composition essential for the targeting to macrophages, has raised con-
siderable interest into their therapeutic efficacy. To this date, there are no clinical trials yet
described which directly compare the various effects and outcomes of imiglucerase and vela-
glucerase therapy, at equal dose and with matched patients. Switch-over of imiglucerase to
velaglucerase therapy has taken place as a consequence of the global shortage in imiglucerase
in 2009, stemming from problems with production [39]. Type I GD patients switching from
Investigations on therapeutic glucocerebrosidases with fluorescent probes
PLOS ONE | DOI:10.1371/journal.pone.0170268 February 16, 2017 2 / 23
Competing interests: JMFGA and HSO are
inventors on a patent application on cyclophellitol
epoxide ABPs. The name of the patent is "Activity
Based Probes (ABPS0 interacting with
glycosidases)" and the patent number is US
9,056,847 B2 (date of patent: June 16, 2015).
There are no further patents, products in
development or marketed products to declare. The
remaining authors have declared that no
competing interests exist. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
Abbreviations: ABP, activity-based probe; AMP-
DNM, N-(5-adamantane-1-yl-methoxy)pentyl)-
deoxynojirimycin; CBE, conduritol beta-epoxide;
ERT, enzyme replacement therapy; (r)GBA,
(recombinant) glucocerebrosidase; GD, Gaucher
disease; imi, imiglucerase; vela, velaglucerase.
imiglucerase to velaglucerase showed no associated changes in clinical responses and parame-
ters as well as biomarkers [40, 41]. There are a few literature reports describing comparative
studies on imiglucerase and velaglucerase by means of crystallography, analytical chemistry
and enzymology [30, 32, 42]. Experiments were also designed to examine binding and uptake
of both recombinant GBA preparations using cultured cell models [42]. Finally, bio-distribu-
tion of intravenously injected rGBAs was studied in mice [43–46] but no comparative data for
both enzymes have been reported.
The documented differences in structure of N-linked glycans of imiglucerase and velaglu-
cerase (predominantly Man(3) versus Man(9) structures, respectively, see Fig 1A) indicate that
significant differences might exist between the two rGBAs, regarding their targeting to macro-
phages and consequently their bio-distribution and efficacy. There has only been a single
study attempting to visualize the fate of intravenously administered therapeutic GBA in a
Gaucher patient and healthy subject [47]. In this seminal investigation, placental, mannose-
terminated GBA (alglucerase) was radio-labeled with 123I, which randomly modifies tyrosine
residues. Gamma scintigraphy was used to visualize the bodily distribution of the therapeutic
enzyme. This approach, despite its intrinsic low resolution, showed convincing accumulation
of GBA in spleen, liver and bone marrow [47]. At present, comparable information on the
widely applied recombinant enzymes imiglucerase and velaglucerase is lacking. More insight
in bio-distribution and targeting to visceral macrophages of these rGBAs is urgently needed
given the high costs of enzyme therapy for Gaucher disease.
We recently developed a new technology to visualize GBA molecules employing activity-
based probes (ABPs) [48]. We demonstrated that fluorescent BODIPY-containing cyclophelli-
tol β-epoxide, hijacking the catalytic double-displacement mechanism of GBA, forms an irre-
versible inhibitor-nucleophile E340 adduct (Fig 1B). Various ABPs have meanwhile been
designed including probes with a green− and red fluorophore, respectively green β-epoxide
ABP 5 and red β-epoxide ABP 6 (Fig 1C) [48]. The covalent labeling of GBA via E340 is highly
specific and detection of fluorescently labeled enzyme is ultra-sensitive (detection limit ~20
Fig 1. Background. N-linked glycan composition of recombinant GBAs imiglucerase (a) and velaglucerase (b) according to refs[30, 32].
(c) Mechanism of irreversible inhibition by β-epoxide ring-opening. (d) Structures of isofagomine (IFG 1), AMP-DNM 2, conduritol β-
epoxide (CBE 3), cyclophellitol 4, and green− and red-fluorescent β-epoxide ABPs 5 and 6 (MDW933, MDW941)[48].
doi:10.1371/journal.pone.0170268.g001
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attomol, or 10−18 mol). The availability of these ABPs allows a defined and subtle labeling of
GBA molecules [48] and analysis of their fate following administration to cells or after intrave-
nous infusion in mice.
Here we report on a comparative investigation of imiglucerase and velaglucerase labeled
with ABPs that fluoresce at different wavelengths. We demonstrate that both enzymes are very
similar in catalytic features while differing in N-linked glycan composition. Binding and
uptake of ABP-labeled imiglucerase and velaglucerase in isolated dendritic cells, cultured
human macrophages and living mice was investigated and the outcome of these investigations
is presented. ABP-labeled imiglucerase and velaglucerase, administered as single enzymes or
as equimolar mixture, were similarly taken up by murine dendritic cells and showed a compa-
rable bodily distribution following intravenous administration to living mice. No striking dif-
ferences were noted between the two rGBAs in the targeting of key organs in the pathology of
type I GD. Enzymes were recovered largely in liver, white-blood cells, bone marrow and
spleen. More detailed investigations on binding and uptake by macrophages were performed
using cultured macrophages, derived from human peripheral blood monocytes. Subtle differ-
ences were noted between the two recombinant enzymes. Our study firstly demonstrates the
value of ABPs to comparatively investigate two rGBAs with respect to their uptake by macro-
phages and bodily distribution following intravenous infusion of mice.
Materials and methods
General methods
ABPs were synthesized as described earlier [48]. Chemicals were obtained from Sigma-Aldrich
if not otherwise indicated. Recombinant GBA was purchased from Genzyme (imiglucerase;
imi) and Shire PLC (velaglucerase; vela). Monoclonal anti-human GBA antibody 8E4 was pro-
duced from hybridoma cells as described earlier [49]. Immature dendritic cells were a kind gift
from the Biopharmaceutics (LACDR) Department of Leiden University. Cell lines were cul-
tured in HAMF12-DMEM medium (Invitrogen) supplied with 10% FBS. Buffy-coats were
purchased from Sanquin Bloodbank (Amsterdam).
Ethics
The appropriate ethics committees for animal experiments approved this study and all experi-
mental procedures including those involved with the isolation of bone marrow derived den-
dritic cells (Leiden University, Leiden, The Netherlands) and the procedures involved with in
vivo biodistribution studies (Academic Medical Center, University of Amsterdam, The
Netherlands).
Enzyme activity assays
The activity of GBA was assayed at 37˚C by incubating with 3.75 mM 4-methylumbelliferyl-β-
D-glucopyranoside (4MU-β-D-Glc) as substrate in 150 mM McIlvaine buffer, pH 5.2, supple-
mented with 0.1% (w/v) BSA, 0.2% (w/v) sodium taurocholate, and 0.1% (v/v) Triton X-100.
Determination of reaction constants was performed by incubating GBA with 0−4 mM 4MU-β-
D-Glc and fitting results to a Michaelis-Menten function. Effect of pH on enzymatic β-glucosi-
dase activity was analyzed by pre-incubating GBA in pH 2−9 for 30 min at 37˚C, whereafter
GBA activity as assayed with 3.75 mM 4MU-β-D-Glc at the same pH. Time-dependent decay
of GBA β-glucosidase activity towards 4MU-β-D-Glc was measured by firstly incubating the
enzyme at pH 5.2 or 7.4, whereafter GBA activity was assayed with 3.75 mM 4MU-β-D-Glc at
pH 5.2. Inhibitory potency of IFG 1, AMP-DNM 2, conduritol β-epoxide (CBE 3), cyclophellitol
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4, and β-epoxide type ABP 5 (MDW933) and ABP 6 (MDW941) was determined by pre-incu-
bating GBA with a range of inhibitor concentrations for 30 min at pH 3–9, where after the resid-
ual GBA β-glucosidase activity was measured by addition of 3.75 mM 4MU-β-D-Glc at pH 5.2.
After stopping each substrate reaction with excess NaOH-glycine (pH 10.3), fluorescence was
measured with a fluorimeter LS55 (Perkin Elmer) using λEX 366 nm and λEM 445 nm.
ABP-labeled rGBA preparations
Concentrations of imiglucerase (imi) and velaglucerase (vela) preparations were determined
with standard 4MU-β-D-Glc assay conditions at pH 5.2 and subsequently labeled for 50% or
90% with either green fluorescent β-epoxide ABP 5 or red fluorescent β-epoxide ABP 6 in 150
mM McIlvaine buffer, pH 5.2 (supplemented with 0.2% (w/v) sodium taurocholate, 0.1% (v/v)
Triton X-100) for 1 h at 37˚C. Unbound β-epoxide ABPs 5 and 6 were removed by washing
thrice with the aforementioned McIlvaine buffer over 30 kDa cut-off filters. Equimolar mixes
were prepared of apo: green ABP 5 or red 6-labeled imiglucerase, apo: red ABP 6-labeled vela-
glucerase and green ABP 5-labeled imiglucerase: red ABP 6-labeled velaglucerase. Total inacti-
vation of each enzyme preparation was quantified by 4MU-β-D-Glc assays, with and without
pre-incubations with spikes of 12.5 μL 10 nM imiglucerase. In parallel, samples were dena-
tured with 5× Laemmli buffer (50% (v/v) 1M Tris-HCl, pH 6.8, 50% (v/v) 100% glycerol, 10%
(w/v) DTT, 10% (w/v) SDS, 0.01% (w/v) bromophenol blue), boiled for 4 min at 100˚C, and
separated by electrophoresis on 7.5% (w/v) SDS-PAGE gel running continuously at 90 V [48,
50]. Wet slab gels were scanned on fluorescence using the Typhoon Variable Mode Imager
(Amersham Biosciences) using λEX 488 nm and λEM 520 nm (band pass filter 40 nm) for
green fluorescent β-epoxide ABP 5 and λEX 532 nm and λEM 610 nM (band pass filter 30 nm)
for red fluorescent β-epoxide ABP 6. ABP-emitted fluorescence was quantified using ImageJ
software (NIH, Bethesda, MD, USA), and verified in-gel by presence of 50 fmol equimolar
green β-epoxide ABP 5– and red 6-labeled imiglucerase.
Immunoprecipitation
Mouse α-human GBA 8E4 [49] was immobilized on Sepharose-ProtA beads in PBS for 1 h at
room temperature (RT) while rotating at 30 rpm, thereafter washed thrice by centrifugation
for 3 min at 500 rpm and rinsed with PBS for 10 min. Samples of 10 μL were immunoprecipi-
tated using 50 μL 8E4-Sepharose-ProtA beads for 1 h at RT, thereafter washed thrice by centri-
fugation for 3 min at 500 rpm and rinsed with PBS for 10 min. Immunoprecipitant and first
supernatant were separated by SDS-PAGE and ABP-labeled proteins were visualized by fluo-
rescence scanning.
Deglycosylation
ABP-labeled proteins were digested with PNGase-F or endo-H, following manufacturers’
instructions (New England Biolabs). After deglycosylation, samples were denatured, separated
by SDS-PAGE and ABP-labeled proteins were visualized by fluorescence scanning.
One/two dimensional SDS-PAGE, gel staining and densitometry
ABP-labeled GBA was precipitated by TCA, re-hydrated (30 mM Tris, 7.7 M urea, 2.2 M thio-
urea, pH 8.9, 4% (w/v) CHAPS, 0.5% (v/v) Destreak agent and 2% (v/v) IPG buffer), soaked
overnight into pH 3−10 nonlinear strips (BioRad). Iso-electric focusing with standard program
(0.1 min at 50 V; 30 min to 200 V; 30 min at 200 V; 30 min to 400 V; 30 min at 400 V; 30 min
to 600 V; 30 min at 600 V; 60 min to 3,500 V; 240 min at 3,500 V; 10 min to 200 V; hold at 200
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V, on Protean IEF (BioRad)) and proteins subsequently separated by SDS-PAGE. One-dimen-
sional SDS-PAGE followed by fluorescent scanning and Coomassie Brilliant Blue (CBB) stain-
ing was exactly performed as described earlier [50]. Fluorescence controls were either based
on excess imiglucerase labeled with 50 fmol green β-epoxide ABP 5 and red 6, denatured,
mixed and loaded on gel as control standard, or based on excess imiglucerase labeled with 100
fmol green β-epoxide ABP 5 and an equimolar amount of velaglucerase labeled with 100 fmol
red 6, denatured, mixed and loaded on gel as control standard.
Bio-distribution study of ABPs in living mice
C57Bl/6J mice were obtained from Charles River (Wilmington, MA, USA) and fed a commer-
cially available lab diet (CRM(E), Special Diet Services, UK). Twelve male C57Bl/6J mice were
intravenously injected by tail-vein injection with PBS vehicle or 1 nmol green ABP 5-labeled
imiglucerase and 1 nmol red ABP 6-labeled velaglucerase. After 0–4 days the mice were anes-
thetized with FFM mix (25/25/50 fentanyl-citrate/midazalam/sterile H2O) and EDTA-blood
was collected from the tail-vein. Mice were then perfused via the heart into the aortic root with
PBS, flowing at 3.0 mL min−1 for 3 min by using a syringe pump (Harvard apparatus, Hollis-
ton, MA, USA), whereafter organs were collected, directly snap-frozen in liquid nitrogen.
Samples were stored at –80˚C until homogenization in 1:5 ratio of tissue-weight to volume of
25 mM potassium phosphate buffer (pH 6.5, 0.1% (v/v) Triton X-100 and protease inhibitor
cocktail (Roche)). Standard tissue homogenization carried out with the organs: brain, liver,
spleen, lungs, thymus, kidney, testis, epididymis, stomach, pancreas, duodenum, brown− and
epididymal fat. Homogenization occurred with 250 μL RNAse-free glass beads in 2 mL screw-
cap Eppendorf tubes, samples were crushed with a TissueLyzer set at 6 m s−1 for 20 s, thrice,
while samples were chilled on ice-slush between runs for 2 min. Lysates were isolated from
glass beads by pipetting into sterile Safe-Lock Eppendorf tubes. After homogenization of adi-
pose tissues, samples centrifuged for 10 min at 10,000 rpm at 4˚C and bottom layer of lysate
was pipetted into sterile Safe-Lock Eppendorf tubes. The top, lipid-rich layer was isolated and
stored separately. Other organs (eye, skin, heart, calf muscle) were first manually cut with a
sterile scalpel and subsequently homogenized by sonication at 50% power, 50% amplitude for
5 s, thrice while samples were identically chilled as decribed, vide supra. Small isolates, i.e. white
blood cells and bone marrow were directly sonicated as described, vide supra. All homogenates
were then aliquoted and directly snap-frozen in liquid nitrogen, or immediately analyzed for
protein concentration (BCA kit, Pierce), in vitro ABP labeling and fluorescence scanning of
SDS-PAGE slab-gels. ABP-emitted fluorescence was quantified using ImageJ software (NIH,
Bethesda, MD, USA), and verified in-gel by presence of 50 fmol equimolar green β-epoxide
ABP 5– and red 6-labeled imiglucerase, and calculated values were corrected for CBB staining
intensity.
Culturing of primary cells
C57Bl/6 mice were deeply anesthetized (see above), tibiae and femurs were collected and bone
marrow of tibiae was flushed out with PBS. Then, immature dendritic cells were grown in den-
dritic cell selection medium (2:1 (v/v) IMDM with granulocyte-macrophage colony stimulating
factor (GM-CSF), containing 8% (v/v) FCS, penicillin/streptomycin (100 U mL–1), glutamax (2
mM) and β-mercaptoethanol (20 μM) with 5% (v/v) CO2 at 37˚C, and sub-cultured every 2–3 d.
Confocal fluorescence microscopy
Immature bone marrow derived dendritic cells cultured 10–12 d ex vivo were seeded at 30–
75 × 104 cells/well into sterile LabTek II 4– or 8-chamber borosilicate cover-glass systems
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(Fisher Emergo). After 2 h, cells were attached and pre-incubated with 300 μM CBE 3 in
absence or presence of 3 μg μL−1 mannan for 1 h. Hereafter, cells were incubated with 50 nM
green ABP 5– or red 6-labeled imiglucerase, velaglucerase, or both labeled with opposite ABPs
(equimolar, 1:1) for 2 h. The ABP-labeling of aforementioned rGBA stocks was 50% (50%
remained apo). Cells were washed twice with PBS and imaged (live cells), before being fixed
with 4% (w/v) p-formaldehyde in PBS, then washed thrice with PBS and finally nuclei were
stained with Draq5 (Fisher Scientific) (fixed cells). Imaging was performed with a Leica TCS
SPE confocal microscope, using GFP, dsRed and Cy5 filter settings (λEX 488, 532, 635 nm,
respectively) with optimized detection range to exclude bleed-through of dye signal in differ-
ent channels. Micrographs were taken sequentially and laser settings, pinhole and PMT were
kept constant in each experiment.
Isolation and maturation of macrophages
Buffy-coats were diluted into PBS supplemented with 0.1% (w/v) BSA and heparin, subsequently
layered on top of Lymphoprep gradient (Stemcell Technologies) and centrifuged at 1,000×g for 15
min at RT. After washing the PBMC pellets with PBS supplemented with 0.1% (w/v) BSA, cells
were centrifuged at 750×g for 10 min at RT, rinsed and repeated at 500×g for 5 min. Hereafter,
pellet is washed with aforementioned PBS, and centrifuged at 250×g for 10 min at RT. Then,
monocytes are separated on a Percoll gradient. Pellet is resuspended in 2.5 mL 60% (w/v) SIP and
then layered with 5 mL 45% (w/v) SIP and 2.0 mL 34% (w/v) SIP), and centrifuged at 1750×g for
45 min at RT. Upper interface containing monocytes is washed thrice with aforementioned PBS,
centrifuged at 500×g for 10 min and then twice at 500×g for 5 minutes. Cell fraction was then
resuspended in RPMI with 1% (w/v) human serum, monocytes counted with tryphan blue solu-
tion and 106 monocytes were seeded per well. After 1 h at 37˚C and 5% (v/v) CO2, non-adhering
non-monocyte cells were washed away with aforementioned PBS and adhered monocytes then
were cultured in RPMI with 10% (v/v) human serum for 7 days prior to experiment initiation.
Initial binding and uptake assays with cultured cells
Monocyte-derived macrophages were incubated with 100 nM green β-epoxide ABP 5– or red
6-labeled imiglucerase for 0–180 min whilst at 18˚C, to block endocytosis, or at 37˚C, to allow
endocytosis. At different time-points, the medium was removed; cells were washed thrice with
ice-cold PBS and subsequently lysed by scraping in 25 mM potassium phosphate buffer (pH
6.5, 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche)). After determination of
the protein concentration, samples were denatured, separated by SDS-PAGE and ABP-labeled
proteins were visualized by fluorescence scanning. ABP-emitted fluorescence was quantified
using ImageJ software (NIH, Bethesda, MD, USA), and verified in-gel by presence of 50 fmol
equimolar green β-epoxide ABP 5– and red 6-labeled imiglucerase, and calculated values were
corrected for CBB staining intensity.
Cell binding assays
First, monocyte-derived macrophages were incubated with 300 μM CBE 3 for 2 h in medium
and washed with PBS. Hereafter, the cells were pre-incubated for 15 min at 18˚C in the pres-
ence or absence of 10 μg μL−1 mannan and subsequently received 0–2,500 nM apo or ABP-
labeled GBA enzyme preparation for 30 minutes at 18˚C. Hereafter medium was removed,
cells were washed thrice with ice-cold PBS and subsequently lysed by scraping in 25 mM potas-
sium phosphate buffer (pH 6.5, 0.1% (v/v) Triton X-100 and protease inhibitor cocktail
(Roche)). ABP-emitted fluorescence was quantified using ImageJ software (NIH, Bethesda,
MD, USA), and verified in-gel by presence of 50 fmol equimolar green β-epoxide ABP 5– and
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red 6-labeled imiglucerase, and calculated values were corrected for CBB staining intensity.
For each separate donor, the apparent KD and BMAX involved in surface binding of each rGBA
was calculated by fitting the equation rGBAsurface-bound = BMAX[rGBAinput] / KD+[rGBAinput] to
the employed input and recovered quantity of rGBA, in the presence or absence of mannan.
Mannan-competed binding was calculated by subtracting the fitted curve of when mannan
was present from the fitted curve of when mannan was absent. Ratios were calculated between
KD and BMAX for imiglucerase and velaglucerase, per individual donor.
Cellular uptake assays
Uptake experiments were performed identically to binding assays, except incubations were
performed at 37˚C. For each donor, apparent KD and BMAX involved in cellular uptake and
surface binding of each rGBA was calculated by fitting the equation rGBAsurface-bound =
BMAX[rGBAinput] / KD+[rGBAinput] to the employed input and recovered quantity of rGBA, in
the presence or absence of mannan. Cellular uptake of each rGBA was calculated by subtract-
ing the curves fitted for the binding only, with mannan-competed binding determined by sub-
tracting the fitted curve of when mannan was present from the fitted curve of when mannan
was absent. Ratios were calculated between KD and BMAX for imiglucerase and velaglucerase,
per individual donor.
Results
ABP-labeling and characterization of imiglucerase and velaglucerase in
vitro
Consistent with earlier literature reports [30, 32], imiglucerase and velaglucerase preparations
were found to be quite similar in enzymatic features. Using 4-methylumbelliferyl β-D-gluco-
pyranoside as artificial substrate, imiglucerase and velaglucerase showed a comparable Vmax
(50.68 and 50.22 nmol min−1 μg−1, respectively), Km (1.828 and 1.837 mM, respectively) and
pH-dependence with an optimal activity at 5.2 (see S1 Fig). The two enzymes were also compa-
rably inactivated by exposure to pH 7.4, i.e. the pH of whole blood. Both preparations prove
equally sensitive to inhibition by the reversible inhibitors isofagomine (IFG 1) and AMP-DNM
2, and similarly inactivated by the irreversible inhibitors conduritol β-epoxide (CBE 3) and
cyclophellitol 4, as assessed at different pH values (see S1 Fig). Importantly, the irreversible
inactivation of imiglucerase and velaglucerase by cyclophellitol β-epoxide type ABP 5 was
identical. Likewise, β-epoxide ABP 6 comparably inactivated imiglucerase and velaglucerase
(S1 Fig). No differences were noted in reactivity of the two rGBAs with the two ABPs. The
inactivation with both ABPs was complete for both enzymes. Since inactivation of GBA by
ABPs implies covalent labeling of the nucleophile E340, we examined the formation of ABP-
labeled enzyme by subjecting rGBAs that had been incubated with β-epoxide ABPs to
SDS-PAGE. Fluorescence scanning of the slab gel showed the presence of ABP-labeled imiglu-
cerase and velaglucerase (Fig 2A, first two lanes).
Imiglucerase and velaglucerase differ in apparent molecular weight with SDS-PAGE due
their difference in N-linked glycans, i.e. predominantly Man(3) and Man(9), respectively.
Even when mixed in a single sample, imiglucerase and velaglucerase are clearly separated by
SDS-PAGE in 7.5% polyacrylamide gels (Fig 2A, e.g. middle lane).
Imiglucerase contains an arginine at position 496 instead of a histidine residue as in vela-
glucerase and wild-type GBA [28–32]. Consequently, imiglucerase does not cross react with
the monoclonal antibody 8E4 [48, 51]. When equal amounts (500 fmol) of imiglucerase and
velaglucerase were labeled with excess green fluorescent β-epoxide ABP 5 or red fluorescent β-
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epoxide ABP 6, immunoprecipitation with 8E4 antibody led to selective removal of velaglucer-
ase (Fig 2A, last two lanes).
Enzymatic removal of N-linked glycans from imiglucerase and velaglucerase with PNGase-
F, results in reduction of molecular weight to ~56 kDa, both for imiglucerase and velaglucerase
(Fig 2B, last lane). Removal of the high mannose-core by endo-H changed the molecular
weight of imiglucerase to approximately 58−59 kDa, in contrast to that of 56 kDa shown by
endo-H digested velaglucerase (Fig 2B, middle lane). Green ABP 5-labeled imiglucerase and
red ABP 6-labeled velaglucerase were mixed equally (1 picomol) and subjected to 2D gel elec-
trophoresis (Fig 2C). Subtle differences in isoforms of imiglucerase and velaglucerase become
apparent with this analysis. Most likely the distinct isoform profiles of both enzymes reflect dif-
ferences in glycan composition, which might influence uptake and/or stability. Swapping β-
epoxide ABP 5 for 6 (and vice versa) for both enzymes did not alter the isoforms or 2D gel elec-
trophoresis patterns (data not shown).
Uptake of ABP-labeled imiglucerase and velaglucerase by murine
dendritic cells
Batches of equal amounts of imiglucerase and velaglucerase were covalently labeled with green
β-epoxide ABP 5 and red ABP 6 while avoiding the presence of excess free β-epoxide ABP (Fig
Fig 2. Labeling of imiglucerase and velaglucerase with ABPs. (a) From left to right: visualized after
SDS-PAGE, imiglucerase labeled with green ABP 5; velaglucerase with red ABP 6; a mixture of both pre-
labeled rGBAs; supernatant of mixture immunoprecipitated with monoclonal 8E4; immunoprecipitate. (b)
Enzymatic deglycosylation of ABP 5-labeled rGBA by PNGase-F and endo-H. Top panel shows imiglucerase,
bottom panel velaglucerase. Every lane contained red ABP 6-labeled rGBA. From left to right: untreated rGBA
labeled with green ABP 5 (yellow color due to overlay with red ABP 6-labeled corresponding enzyme);
PNGase-F treated rGBA labeled with green ABP 5 and endo-H treated rGBA labeled with green ABP 5. (c)
Two-dimensional gel electrophoresis of equimolar mixture of green ABP 5-labeled imiglucerase and red ABP
6-labeled velaglucerase (Detail; right).
doi:10.1371/journal.pone.0170268.g002
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3A). Quantification of ABP-emitted fluorescence resulted in 155.8 ± 0.6 arbitrary fluorescence
units (AU) per fmol β-epoxide ABP 5 or 6, for both imiglucerase or velaglucerase (Fig 3B).
Next, murine bone marrow-derived dendritic cells, known to contain mannose-binding
lectin(s), were treated with green β-epoxide ABP 5-labeled imiglucerase or red ABP 6-labeled
velaglucerase, in the absence and presence of mannan, which is a competitor for mannose-
Fig 3. Uptake of ABP-labeled rGBAs by dendritic cells. (a) ABP 5− and 6-labeled imiglucerase and velaglucerase. (b) Arbitrary units of
fluorescence (AU) quantified per fmol ABP-labeling of imiglucerase (open columns) and velaglucerase (closed columns). (c) CSLM
micrographs of fixed murine bone marrow-derived immature dendritic cells after 30 min uptake of green ABP 5-labeled imi and red ABP
6-labeled vela in absence (top row) and presence of 1 μg/μL mannan (bottom row). Nuclei in blue (Draq5 staining). Micrographs were
merged with bright-field microscopic image. Scale-bar represents 25 μm. (d) Uptake of equimolar mixture of green ABP 5-labeled imi and
red ABP 6-labeled vela without and with 1 μg/μL mannan (left and right column, respectively), analyzed when fixed. Equal green and red
fluorescence yields yellow overlay. Scale-bar represents 25 μm. (e) Dynamic endocytosis of equimolar mixture of ABP 5-labeled imi and
ABP 6-labeled vela as registered in living cells (left column). Arrows show shift in red ABP 6 and green ABP 5-labeled rGBA visualized at
different time-point. Right column: identical experiment but with fixed cells prior to fluorescence acquisition. Asterisk depicts nucleus, scale-
bar represents 7.5 μm. (f) Dynamic uptake of ABP-labeled rGBA, visualized by primary 75-minute pulse of red ABP 6-labeled imi followed
by washing and secondary 75-minute pulse of green ABP 5-labeled imi. Asterisk depicts nucleus, scale-bar represents 25 μm.
doi:10.1371/journal.pone.0170268.g003
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binding lectin-dependent uptake (Fig 3C). After thorough washing and subsequent fixation,
the subcellular distribution of fluorescent enzyme was determined. Both enzymes were avidly
taken up in the dendritic cells in the absence of mannan (Fig 3C, top row) with no apparent
differences in subcellular localization. The presence of mannan completely inhibited uptake of
either ABP-labeled rGBA (Fig 3C, bottom row). The same findings were made for red ABP 6-
labeled imiglucerase and green β-epoxide ABP 5− and red ABP 6-labeled velaglucerase (data
not shown).
In a similar experiment, dendritic cells were incubated with an equimolar mixture of green
β-epoxide ABP 5-labeled imiglucerase and red ABP 6-labeled velaglucerase, with a comparable
outcome (Fig 3D, left column). Both green and red rGBAs were taken up with approximately
similar efficiency, resulting in a yellow overlay. Uptake of the rGBAs into the dendritic cells
was completely competed by mannan (Fig 3D, right column).
Live-cell imaging, thus without fixation, suggested uptake of ABP-labeled imiglucerase and
velaglucerase occurs in the same vesicle (Fig 3E, left column). While acquiring the micrographs,
firstly red ABP 6-emitted fluorescence was detected; the apparent shifts of red and green
labeled structures in the two stills suggest movement of vesicles in the period of time between
the red and green fluorescence data acquisition (Fig 3E, detail, see bottom left and arrows).
When fixing the cells with 4% (w/v) p-formaldehyde, the earlier observed shifts between red
and green fluorescence were absent: labeled imiglucerase and velaglucerase co-localized
completely (Fig 3E, right column). The dynamic process of rGBA internalization by endocyto-
sis was visualized by a pulse-pulse experiment, consisting of firstly exposing cells to ABP 6-
labeled imiglucerase for 75 min, followed by washing and exposure to fresh medium contain-
ing ABP 5-labeled imiglucerase for 75 min. As can be seen in Fig 3F, vesicles can be observed
containing predominantly ABP 5 or 6-labeled imiglucerase, or both. After 150 min, the vesi-
cles positive in ABP 6-labeled imiglucerase tend to be in closer proximity to the nucleus com-
pared to those containing predominantly ABP 5-labeled imiglucerase, (Fig 3F, detail).
Binding of ABP-labeled rGBAs by human monocyte-derived
macrophages
To characterize the targeting of rGBAs to macrophages and their subsequent uptake of rGBAs
in more detail, we performed a series of experiments with macrophages derived from human
peripheral blood monocytes (detailed data for cells of individual donors in such experiments are
provided in S3–S6 Figs). For these experiments we used rGBA concentrations in the same range
as expected to occur in type I GD patients during infusion. Patients usually receive doses of 30–
60 IU kg−1 bodyweight during an infusion of one hour. If all of the administered enzyme would
accumulate in plasma, this would lead to concentrations of 40–80 nM. In reality, the steady-state
concentration during the infusion is usually much lower, in the range of 5–20 nM, as the result
of ongoing uptake into cells and slow infusion (Aerts et al., unpublished observations).
To determine binding, we firstly incubated human monocyte-derived macrophages with
100 nM green β-epoxide ABP 5-labeled imiglucerase at 18˚C. As shown in Fig 4A, binding was
saturated at around 30 minutes. Enzyme binding was dose-dependent in the range 0–100 nM
labeled rGBA (Fig 4B). Comparison of binding of green β-epoxide ABP 5– and red ABP 6-
labeled imiglucerase concomitantly administrated (Fig 4C and 4D) indicated the binding affin-
ity of the two ABP-labeled rGBAs is similar and thus binding is not influenced by the fluoro-
phore incorporated into the ABP.
Uptake of ABP-labeled rGBA at 37˚C was proportional to binding at 18˚C (see S2 Fig).
Incubation of the same cells with 100 nM green β-epoxide ABP 5-labeled imiglucerase at 37˚C
showed that uptake was linear over time, up to 3 hours (S2 Fig). The same was observed for
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incubation of cells with mixtures of green ABP 5− and red ABP 6-labeled imiglucerase (see S2
Fig). Similar observations were made for binding and uptake by using unlabeled, i.e. apo, imi-
glucerase and ABP 5-labeled imiglucerase (Data not shown).
Next, we analyzed the effect of mannan (10 μg μl−1) on binding and uptake of ABP-labeled
rGBAs. Experiments were performed with macrophages differentiated monocytes isolated
from blood samples of twelve healthy human donors. Binding of apo rGBAs was determined
Fig 4. Binding of ABP-labeled imiglucerase to macrophages. (a) Time-dependent binding of green β-epoxide ABP 5-labeled imiglucerase
to macrophages at 18˚C. (b) Dose dependence of binding of green β-epoxide ABP 5-labeled imiglucerase to macrophages at 18˚C. (c)
Binding of mixtures of green ABP 5− and red ABP 6-labeled imiglucerase. (d) Quantification of c: cell-bound green ABP 5-imiglucerase at 18˚C
related to input (green closed square); cell-bound red ABP 6-imiglucerase at 18˚C related to input (red closed circle). Data are average of
duplicate experiments, ±SD. Effect of mannan on binding of ABP-labeled rGBAs. (e) Binding of 10−2,500 nM imiglucerase and velaglucerase
at 18˚C in the presence and absence of mannan (10 μg μL−1) shown for human monocyte-derived macrophages from one random donor
(Donor III). From top to bottom: unlabeled (apo) imiglucerase post-labeled with green ABP 5; apo velaglucerase post-labeled with red ABP 6;
pre-labeled green ABP 5 imiglucerase and pre-labeled red ABP 6-velaglucerase. Fluorescence was calibrated with 50 fmol equimolar ABP 5
− and 6-labeled imi present on each SDS-PAGE gel (asterisk). (f) Quantification of e; see S3 Fig for binding data of n = 12 donors. (f) Binding
of equimolar 10−2,500 nM imiglucerase and velaglucerase at 18˚C in the presence and absence of mannan (10 μg μL−1) shown for human
monocyte-derived macrophages from one donor with green ABP 5-labeled imiglucerase and red ABP 6-labeled velaglucerase. Fluorescence
was calibrated with 50 fmol equimolar ABP 5− and 6-labeled imi present on each SDS-PAGE gel (asterisk). (h) Quantification of g; see S4 Fig
for binding data of n = 12 donors.
doi:10.1371/journal.pone.0170268.g004
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in the absence and presence of mannan. For this, cells were prior treated with excess CBE 3 for
2 hours to block the E340 nucleophiles of all endogenous GBA, next cells were washed and
finally incubated at 18˚C for 30 minutes with apo 10–2,500 nM imiglucerase or velaglucerase
in the absence or presence of mannan (Fig 4E). Cell-bound rGBA was visualized by labeling
with fluorescent ABPs: green β-epoxide ABP 5 in the case of imiglucerase and red β-epoxide
ABP 6 in the case of velaglucerase. As can be seen in Fig 4E (upper panels), the presence of
mannan hardly competed imiglucerase binding, but prominently inhibited surface binding of
velaglucerase. The same observations were made with pre-labeled imiglucerase and velaglucer-
ase (Fig 4E, lower panels). Binding of the former was hardly competed by mannan, but not that
of pre-labeled velaglucerase (S3 Fig).
For fluorescence quantification and apparent KD en BMAX constants, see Fig 4F and
Table 1, respectively. Similar trends were noted for cells of various donors. It can be seen in S7
Fig (ratios of imiglucerase versus donors velaglucerase) that inter-individual differences were
noted in mannan-competed and non-competed binding of rGBAs. However, a larger man-
nan-competed binding of velaglucerase was always observed, as well as a larger mannan non-
competed binding of imiglucerase. The finding that apo and pre-labeled rGBAs behaved
entirely identical (see Fig 4E and 4F and Table 1) demonstrates that attachment of a β-epoxide
ABP to the nucleophile E340 in the catalytic pocket does not influence recognition of enzyme
by receptors involved in binding and uptake.
The same experiments were performed while incubating cells with equimolar green β-epox-
ide ABP 5-labeled imiglucerase and red ABP 6-labeled velaglucerase (Fig 4G and 4H). Again,
in this direct comparison of the two rGBAs, the mannan-competed binding was highest for
velaglucerase (see also S7 Fig).
The effect of mannan on uptake of rGBAs by monocyte-derived macrophages was com-
pared next. Hereto, human monocyte-derived macrophages were assayed with the exact same
protocol (vide supra), except that incubation with the different enzyme mixtures occurred for
30 min at 37˚C, allowing endocytosis to take place. As shown in Fig 5A and 5B, uptake of vela-
glucerase and imiglucerase, either apo or ABP-labeled, was different. Similar to the difference
noted with binding, uptake competed by mannan was highest for velaglucerase, and uptake
not competed by mannan was highest for imiglucerase. This is depicted also in Fig 5C for cells
from identical donor as highlighted in Fig 4. Similar trends were seen for cells from other
donors (see S8 Fig). Very similar findings were made when cells were exposed to mixtures of
pre-labeled imiglucerase and velaglucerase (see Fig 5D–5F; also S9 Fig and S10 Fig).
Bodily distribution of ABP-labeled imiglucerase and velaglucerase
Finally, we studied the bio-distribution of imiglucerase and velaglucerase in living mice, by
injecting twelve male, GBA wild-type (C56Bl6/J) mice intravenously in the tail vein with PBS
Table 1. Binding parameters.
Mannan
Competed Non-competed
rGBA Apparent KD BMAX Apparent KD BMAX
imiglucerase 36.87 0.087 111.1 0.397
velaglucerase 359.9 0.434 215.9 0.556
Ratio 0.102 0.200 0.515 0.713
Apparent KD and BMAX of mannan competed− and non-competed binding. Effect of mannan on binding of equimolar ABP-labeled imiglucerase and
velaglucerase.
doi:10.1371/journal.pone.0170268.t001
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vehicle or an equimolar mixture of 1 nanomole green β-epoxide ABP 5-labeled imiglucerase
and red β-epoxide ABP 6-labeled velaglucerase. The animals were sacrificed after 5, 10, 20, 30,
60, 120, 240, 480 minutes and 1, 2 and 4 days post-injection with the ABP-labeled rGBA mix-
ture. At each time-point, mice were anesthetized where after EDTA blood was taken via the
tail vein, and urine and various tissues were collected following a perfusion via the heart with
PBS. Tissue homogenates were prepared, equal amounts (10 μg total protein) were separated
on SDS-PAGE gels in order to resolve the resident levels of fluorescent ABP-labeled imiglucer-
ase and velaglucerase, and detected via fluorescence scanning of the slab-gel (Fig 6A).
The experiment revealed the half-life of both labeled rGBAs in plasma is approximately 10–
15 minutes (Fig 6A, top row). Quantification of the ABP-emitted fluorescence, revealed the
concentrations of both rGBAs were highest in the liver (see Fig 6B), followed by white-blood
cells (WBC), bone marrow, spleen and kidney. With the mass of each isolated tissue, we deter-
mined most of the administered rGBA dose was recovered in the liver (88−93%), spleen (1.9
−2.6%) and bone marrow (1.8−2.3%). In other organs, far less enzyme per amount of total pro-
tein was found, including the lungs. Barely detectable levels of enzyme were detected in brain
and eye, which correlates with previous reports (see Fig 6B).
Fig 5. Effect of mannan on uptake of ABP-labeled rGBAs. (a) Binding and uptake of 10−2,500 nM imiglucerase and velaglucerase
at 37˚C in the presence and absence of mannan (10 μg μL−1) shown for human monocyte-derived macrophages from Donor III (at
random, see results Fig 4). From top to bottom: unlabeled (apo) imiglucerase post-labeled with green ABP 5; apo velaglucerase post-
labeled with red ABP 6; pre-labeled green ABP 5 imiglucerase and pre-labeled red ABP 6-velaglucerase. Fluorescence was calibrated
with 50 fmol equimolar ABP 5− and 6-labeled imi present on each SDS-PAGE gel (asterisk). (b) Quantification of a, subtracted was the
binding observed at 18˚C (see Fig 4F). See S5 Fig for uptake data of n = 12 donors. (c) Maximal cellular imiglucerase (open column)
and velaglucerase (closed column) competed and non-competed by mannan. (d) Binding and uptake of equimolar 10−2,500 nM
imiglucerase and velaglucerase at 37˚C in the presence and absence of mannan (10 mg/mL) shown for human monocyte-derived
macrophages from one donor with green ABP 5-labeled imiglucerase and red ABP 6-labeled velaglucerase. Fluorescence was
calibrated with 50 fmol equimolar ABP 5− and 6-labeled imi present on each SDS-PAGE gel (asterisk). (e) Quantification of d,
subtracted was the binding at 18˚C (see Fig 4I). See S5 Fig for uptake data of n = 12 donors. (f) Maximal cellular imiglucerase (open
column) and velaglucerase (closed column), competed and non-competed by mannan.
doi:10.1371/journal.pone.0170268.g005
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Importantly, no significant differences between imiglucerase and velaglucerase were
observed, albeit marginally more imiglucerase localized in the liver than velaglucerase, while
increased levels of the latter were identified in WBC, spleen and bone marrow.
Within approximately one hour post-injection, the amount of rGBAs per tissue reached its
maximum. The apparent half-life of both labeled rGBAs was tissue-dependent (Fig 6C). A bi-
phasic decay was noted for each investigated tissue, with generally a shorter half-life of about
~60−90 min and a much longer one (~12−18 hours, or more).
Discussion
A rational concept for therapy of Gaucher disease is the chronic supplementation of lysosomes
of storage macrophages with GBA.
To this end, the N-linked glycans of therapeutic GBAare modified to expose terminal man-
nose-moieties allowing uptake by mannose-receptor rich macrophages. Chronic intravenous
administration of mannose-terminated GBA results in impressive clinical responses in type I
GD patients. This has stimulatedcomparable enzyme therapy approaches for the treatment of
Fig 6. Bio-distribution of ABP-labeled rGBAs in living mice at different time-points. Wild-type male C57Bl/6J mice were injected with
equimolar mixture of 1 nmol green β-epoxide ABP 5-labeled imiglucerase (imi) and red β-epoxide ABP 6-labeled velaglucerase (vela). The
animals were sacrificed after 5, 10, 20, 30, 60, 120, 240, 480 minutes and 1, 2 and 4 days. (a) SDS-PAGE of tissues, with WBC as white-blood
cells. Per tissue, equal amounts (10 μg) of protein were applied in every lane. Fluorescence was calibrated with 50 fmol equimolar green β-
epoxide ABP 5-labeled imiglucerase and red β-epoxide ABP 6-labeled velaglucerase present on each SDS-PAGE gel (asterisk). (b) Tissue-
level of ABP-labeled rGBA at one hour post-injection, ranked highest to lowest. ABP 5-labeled imiglucerase (open columns) and ABP 6-labeled
velaglucerase (closed columns). (c) Quantification of ABP-fluorescence from a: ABP 5-labeled imiglucerase (open circles) and ABP 6-labeled
velaglucerase (closed squares).
doi:10.1371/journal.pone.0170268.g006
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other inherited lysosomal storage disorders such as Pompe disease [52], Fabry disease [53] and
MPS disorders [54–56]. Enzyme therapy of type I GD presently employs recombinant glucocer-
ebrosidases (rGBAs) produced in different platforms: imiglucerase, velaglucerase and taliglucer-
ase. The various rGBAs all contain mannose-terminated N-linked glycans, but differences exist
in the exact structures ranging from Man(3), Man(9) to plant-type high-mannose glycans.
There is a present need for sensitive and comparative monitoring of the various therapeutic
enzymes in pre-clinical and clinical studies. Particularly required is a method for non-invasive
monitoring of tissue-distribution of rGBAs in individual type I GD patients. In connection to
this, a new methodology for ultra-sensitive visualization of GBA has recently been developed.
GBA can be subtly labeled through covalent attachment of fluorescent activity-based, cyclophel-
litol β-epoxide type, probes (ABPs) to its catalytic nucleophile E340. We have exploited such
ABPs for comparative investigations of the two widely applied rGBAs in Europe: imiglucerase
(Genzyme) and velaglucerase (Shire PLC).
Our investigation demonstrates that imiglucerase and velaglucerase can be conveniently
labeled with fluorescent ABPs. ABP labeled rGBAs were found to behave similar to unlabeled
enzyme in binding and uptake experiments with cultured denditric cells and macrophages. Of
note, earlier non-specific labeling of rGBAs either by iodination or cross-linking fluorescent
Oregon Green or Alexa Fluor was also reported not to affect binding and uptake [45, 57].
Since the enzymes can be selectively tagged with red− and green BODIPY fluorophores, mix-
tures of differently labeled rGBAs can be used for paired measurements and evaluation. When
administered to cells expressing mannose-binding lectin(s), both rGBAs are avidly endocy-
tosed, and this process is partly competed by mannan. Imiglucerase and velaglucerase con-
comitantly administered at equal dose to mice by intravenous infusion show a comparable
tissue-distribution. The uptake of mannose-terminated rGBAs is thought to be mediated by
the mannose-receptor [4, 16–18, 30, 32, 42–47, 57–64]. However, in recent years it has become
apparent that multiple mannose-binding lectins exist in man. Besides the mannose receptor,
also DC-SIGN, langerin, dectin 2 and others can potentially bind terminal mannose-contain-
ing structures [64–66]. The specificity of these various receptors for particular N-linked
glycans is not well documented. Information is also limited regarding cell-type specific expres-
sion of the various receptors in man [67, 68]. Imiglucerase, velaglucerase and taliglucerase
differ in N-linked glycan structures (for an overview see Fig 1A, Bruhmstein et al. [30] and
Tekoah et al. [32]). It is therefore a priori unclear which mannose-binding lectins are responsi-
ble for binding and uptake of the various rGBAs in GD patients. Of interest, Gaucher cells in
spleen of type I GD patients have been shown to express very little of the conventional man-
nose-receptor [69].
In a number of studies, binding and uptake of GBA by macrophages was investigated [28,
30, 32, 42, 43, 45, 46, 57–59, 61–63]. Unfortunately, different GBA preparations (alglucerase,
imiglucerase, velaglucerase and taliglucerase) at different doses were incubated with different
cells, e.g. differentiated cell-lines like U937, alveolar and peritoneal macrophages from mice
and rats, as well as human monocyte-derived macrophages, hampering a direct comparison of
reported data.
We comparatively studied binding and uptake of ABP-labeled imiglucerase and velaglucer-
ase in cultured cells, including paired measurements. First we investigated the uptake of both
rGBAs inmurine dendritic cells, showing comparable mannan-competitive uptake with con-
tinuous co-localization of both enzymes in intracellular structures. Next, we used human
monocyte-derived macrophages as cell model system, allowing us to determine inter-individ-
ual differences. The initial rate of uptake of rGBAs by culture human monocyte-derived mac-
rophages is impressive. When incubating monocyte-derived macrophages with 100 nM ABP-
labeled imiglucerase or velaglucerase, cells endocytosed ~0.8 pmol GBA per million cells. For
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comparison, the amount of endogenous GBA in the same macrophages is an estimated ~0.25
pmol GBA per million cells. At a non-saturating concentration of 100 nM, small differences
were noted between imiglucerase and velaglucerase: the binding and uptake of velaglucerase
was slightly higher as observed with cells from twelve distinct healthy donors. Sato and Beutler
also noted two distinct mannose-dependent uptake mechanisms for alglucerase in human
monocyte-derived macrophages [57]. The KD of the high-affinity mechanism was 120 nM
[57]. Friedman et al. studying rat alveolar macrophages observed a KD for mannan-competed
binding of alglucerase of 13 nM [62]. In our cell model, the KD of mannose-dependent binding
was approximately ~88 nM for imiglucerase and ~162 nM for velaglucerase, probably reflect-
ing a mixture of different mechanisms. Of further note, binding and uptake of rGBAs was only
partly dependent on mannose-binding lectins. Particularly in the case of imiglucerase, signifi-
cant binding and uptake still occurred in the presence of mannan. Recently the membrane
protein LIMP-2 has been identified as a candidate receptor in glycan-independent binding
and uptake of rGBA by blood cells [70]. LIMP-2 is already known to govern transport of newly
formed GBA from the endoplasmic reticulum to the lysosome [71].
The relevance of the findings made with cultured macrophages for uptake of therapeutic
enzyme in patients is still unclear. The bio-distribution of rGBAs has been studied in rodents.
In rats, infusion of alglucerase was found to result in prominent delivery of enzyme to the liver
[59, 60]. In this tissue, most of the enzyme was recovered in sinusoidal endothelial cells and in
Kupffer cells. Hepatic sinusoidal endothelial cells are known to express the mannose-receptor
[59, 72–74], explaining their prominent uptake of mannose-terminated GBA. Uptake of man-
nose-terminated GBA by hepatic sinusoidal endothelial cells was further confirmed in later
studies [46, 58, 62]. The half-life of alglucerase in plasma of rats was found to be remarkably
short, around 2–5 minutes [59], mimicking the values of 3–12 min observed in type I GD
patients (Aerts et al., unpublished observations). Similar findings have been made with mice
[43]. A large portion of infused alglucerase was recovered in the liver (60%) and spleen (20%)
[43]. Maximal amounts were noted about 20 minutes post-infusion. More recently, Shaaltiel
and co-workers [32] reported on the comparison between imiglucerase, velaglucerase and
taliglucerase each administered to mice at a dose of 90 IU kg–1. Similar findings were made
regarding bio-distribution, which was identical for all three rGBAs. van Patten et al. [45] pro-
duced in various expression systems rGBAs with different mannose-type N-linked glycans rang-
ing from Man(2) to Man(9). No difference was observed among the enzymes regarding affinity
to the mannose-receptor, macrophage uptake and intracellular half-life. In a Gaucher mouse
model (D409V/null), neither striking differences were seen for clearance or tissue-distribution
of the various rGBAs [45]. Our present study with ABP-labeled imiglucerase and velaglucerase
recapitulates the earlier findings in many aspects. We administered to mice 1 nanomol (3 IU) of
ABP-labeled imiglucerase and velaglucerase each (i.e. 100 IU kg–1), mimicking enzyme doses
administered to human Gaucher patients (30–60 IU kg–1). Both administered enzymes showed
a short plasma half-life (10–15 min). Liver (88−93%), spleen (1.9−2.6%) and bone marrow (1.8
−2.3%) contained most of the infused enzyme, both with imiglucerase and velaglucerase. The
amount of both rGBAs was maximal in most tissues at 60 minutes post-infusion.
The animal studies rendered some insight in stability of infused enzyme. Murray and co-
workers [60], and independently Xu and colleagues [43], reported a bi-phasic decay of alglu-
cerase with a short half-life of 45 min and a longer one of 12 hours. Shaaltiel and co-workers
[32], studying intravenous infusions of imiglucerase, velaglucerase and taliglucerase in mice,
observed for all three rGBAs a rapid decay of tissue enzyme activity, being around 50% at 60
min post-infusion as compared to the maximal level at 20 minutes post-infusion [32]. Of inter-
est, the half-life for endogenous GBA in cultured fibroblasts is known to be significantly lon-
ger, being around two days. It is unclear whether the rapid decrease of rGBA in tissues noted
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in various studies is due to regular proteolytic breakdown in lysosomes. Alternatively, the
administered exogenous enzyme could be handled differently from normal endogenous GBA
that reaches lysosomes bound to LIMP-2. It cannot be excluded that exogenous GBA is partly
released from some cell types by endosomal or lysosomal exocytosis, or is subjected to specific
degradation. A similar conclusion regarding a distinct fate of endogenous GBA and exogenous
GBA was earlier drawn by Murray and co-workers [60]. Piepenhagen et al. [46] non-specifi-
cally labeled alglucerase and imiglucerase with Oregon Green 488 and Alexa Fluor 546 carbox-
ylates using succinimidyl-esters [46]. Prominent delivery of tagged GBAs to Kupffer cells and
sinusoidal endothelial cells in the livers of infused mice was observed. In our investigation we
employed GBAs specifically labeled in their catalytic pocket. There is strong evidence that the
lysosomal stability of GBA is markedly improved by such ABP labeling (Kallemeijn et al., sub-
mitted for publication). A similar phenomenon is observed with ABP labeling of the β-glucosi-
dase EGCase II [75]. Infused ABP-labeled rGBAs in all tissues of mice showed a bi-phasic
decay with a very long half-life (>12 hours), possibly partly due to ABP-mediated stabilization,
and a much shorter one of ~60−90 min.
Information on the tissue-distribution and half-life of rGBA following infusion of GD
patients is at present almost completely indirect. Clinical responses have been used to speculate
on delivery of rGBA to particular tissues. Reductions in liver and spleen volumes are thought
to reflect local supplementation with rGBA. Beneficial responses in hematological parameters
and skeletal disease are believed to point to targeting of enzyme to the bone marrow. The lack
of response in neurological manifestations to enzyme therapy is ascribed to inability of the
rGBAs to reach neuronal cells. Only in a single type I GD patient, the tissue-distribution of
123I-modified placental GBA (alglucerase) was visualized. Delivery of enzyme to liver, spleen
and bone marrow was demonstrated. Autopsy materials of two type II GD patients, treated
with alglucerase 48 hours prior to death, have been examined suggesting delivery of enzyme to
liver and spleen, but not to lung and brain [76]. Comparable data for the widely applied rGBAs
are completely lacking.
Our investigation supports the notion that it is feasible to monitor in Gaucher patients the
tissue-targeting of infused rGBAs pre-labeled with a fluorophore-containing ABP. We are
presently designing ABPs bearing fluorophores suitable for whole-body in vivo detection of
labeled enzyme via infrared imaging. Alternatively, other tags linked to the ABP may be con-
sidered to permit non-invasive whole body monitoring such as positron-emission tomography
(PET) tags [77] or single photon emission computed tomography (SPECT) probes [78, 79].
Dual isotope SPECT methods (for example combining 177Lu and 111In-labels) would allow even
simultaneous in vivo determination of the bio-distribution of two different recombinant
enzymes [79]. With such methods in place it should become possible to study in more detail
the targeting of the present rGBAs with distinct mannose-terminated N-linked glycans.
Conclusion
Fluorescent activity-based probes can be used to label different rGBAs in a defined manner,
allowing the simultaneous monitoring of binding of various rGBA types onto the cellular sur-
face of macrophages and uptake therein, even tissue-distribution in laboratory animals (Fig 6).
We noted slight differences between the rGBA preparations of imiglucerase and velaglucerase,
in terms of their binding and uptake within monocyte-derived macrophages, along with their
in vivo biodistribution, however direct paired microscopic analyses did not reveal differences
in their cellular localization. The technological approach could be further developed into a
procedure for non-invasive monitoring of whole-body distribution of rGBAs using trace
amounts of labeled enzyme with a tailor-made tag for detection.
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